23 Breast Cancer Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Breast Cancer Studies in Tucson

NCT03053193Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing ...

Tucson, AZ30,000 participantsAgendia

View Study Details

NCT05952557Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high ...

Tucson, AZPHASE35,500 participantsAstraZeneca

View Study Details

NCT01042379Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learn...

Tucson, AZPHASE25,000 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT06492616Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal G...

Tucson, AZPHASE34,220 participantsStemline Therapeutics, Inc.

View Study Details

NCT06058377Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-I...

Tucson, AZPHASE33,680 participantsNational Cancer Institute (NCI)

View Study Details

NCT06966700Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Earl...

Tucson, AZPHASE32,400 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07060807Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally a...

Tucson, AZPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07174336Recruiting

A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of LY4064809 to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal gr...

Tucson, AZPHASE3920 participantsEli Lilly and Company

View Study Details

NCT04862663Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Fact...

Tucson, AZPHASE3895 participantsAstraZeneca

View Study Details

NCT05232916Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...

Tucson, AZPHASE3750 participantsGreenwich LifeSciences, Inc.

View Study Details

NCT03723928Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread t...

Tucson, AZNA739 participantsSWOG Cancer Research Network

View Study Details

NCT07214532Recruiting

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome")...

Tucson, AZNA725 participantsNatera, Inc.

View Study Details

NCT03954431Recruiting

High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)

This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly. The investigat...

Tucson, AZNA600 participantsUniversity of Arizona

View Study Details

NCT05696626Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- ...

Tucson, AZPHASE3600 participantsSermonix Pharmaceuticals Inc.

View Study Details

NCT06435429Recruiting

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the...

Tucson, AZPHASE3550 participantsJazz Pharmaceuticals

View Study Details

NCT06016738Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whos...

Tucson, AZPHASE3510 participantsOlema Pharmaceuticals, Inc.

View Study Details

NCT05676255Recruiting

The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project

Many breast cancer survivors (estimated 70% in some studies) experience clinically significant depression and/or anxiety in the months and years after finishing cancer treatments. This research will b...

Tucson, AZPHASE2452 participantsUniversity of Arizona

View Study Details

NCT06230185Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR...

Tucson, AZ422 participantsPersonalis Inc.

View Study Details

NCT06072612Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physi...

Tucson, AZPHASE3404 participantsBriaCell Therapeutics Corporation

View Study Details

NCT05715255Recruiting

Adaptive Symptom Self-Management Immunotherapy Study

The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treat...

Tucson, AZNA400 participantsUniversity of Arizona

View Study Details

NCT06184750Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well establi...

Tucson, AZPHASE2200 participantsNational Cancer Institute (NCI)

View Study Details

NCT07007559Recruiting

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in partic...

Tucson, AZPHASE2120 participantsALX Oncology Inc.

View Study Details

NCT06568692Recruiting

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metas...

Tucson, AZPHASE290 participantsProcessa Pharmaceuticals

View Study Details

About Breast Cancer Clinical Trials in Tucson

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 23 breast cancer clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 60,177 participants. Research is being sponsored by Agendia, AstraZeneca, QuantumLeap Healthcare Collaborative and 15 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Tucson — FAQ

Are there breast cancer clinical trials in Tucson?

Yes, there are 23 breast cancer clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 23 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated July 18, 2026 from ClinicalTrials.gov